Magnetic blood filtration for the treatment of anti-biotic resistant bacterial Sepsis

MediSieve正在开发“SepSieve”，这是一种通过直接从患者血液中去除特定致病成分来治疗败血症的新方法。这个过程类似于透析--患者的血液通过一个体外循环回路循环，通过MediSieve的系统，专门针对和提取不需要的物质。这个项目的重点是开发和验证一种抗体包被的磁性颗粒（Ab-MP），可以针对抗微生物耐药性（AMR）革兰氏阴性菌（E.在这个项目中）。这些相同的Ab-MP也将能够结合脓毒症内毒素（LPS）。结合MediSieve现有的磁性血液过滤器，这些Ab-MP将能够从血液中靶向并清除AMR脓毒症的两个根本原因：细菌和LPS共同引起脓毒症特征的过度活跃的免疫反应。如果这种反应得不到控制，患者可升级为脓毒症休克，引起器官衰竭和死亡。专家们特别关注脓毒症引起的AMR菌株的影响。由于抗生素是主要的一线治疗药物，耐药性感染（如MRSA）对公众、患者及其周围的人构成严重威胁。作为一种纯物理方法，MediSieve的SepSieve系统可以避免抗生素耐药性，提供一种可用于严重耐药病例的治疗方法。SepSieve将通过大大加快患者血液中AMR细菌和LPS的清除率，减少患者痛苦，降低总治疗成本和死亡率，改善耐药和非耐药脓毒症的结局。该项目支持MediSieve的Ab-MP的开发，以结合血液中的LPS和细菌。它们将在实验室和动物试验中进行测试，验证它们在清除LPS和AMR E能力方面的安全性和有效性。在完全整合到MediSieve的体外皮质磁性血液过滤系统之前，在该项目结束时，该产品将准备首次在人体临床试验。

MediSieve is developing "SepSieve" a novel method of treating sepsis by removing specific diseases-causing components directly from patient's bloodstreams. The process is similar to dialysis - a patient's blood is circulated through an extra-corporeal loop, passing through MediSieve's system which specifically targets and extracts unwanted substances.The focus of this project is to develop and validate an antibody coated magnetic particle (Ab-MP) that can target anti-microbial resistant (AMR) gram-negative bacteria (E. coli in this project). These same Ab-MPs will also be able to bind the sepsis endotoxins (LPS). Combined with MediSieve’s existing magnetic blood filter, these Ab-MPs will enable the targeting and removal from the bloodstream of two of the root causes of AMR sepsis: bacteria and LPS together cause the overactive immune response that is characteristic of sepsis. If this response is not controlled, the patient can escalade to sepsis shock, causing organ failure and death.Experts are particularly concerned about the impact of sepsis caused AMR strains of bacteria. Since antibiotics are the main frontline treatment, resistant infections (such as MRSA), pose a serious threat to the public, patients and those around them. As a purely physical method, MediSieve's SepSieve system can circumvent antibiotic resistance, providing a treatment that can be used in serious resistant cases. SepSieve would improve outcomes in both resistant and non-resistant Sepsis, by greatly accelerating the clearance rate of AMR bacteria and LPS from the patient’s bloodstream, reducing patient suffering, total treatment costs and mortality rates.This project supports the development of MediSieve's Ab-MPs to bind to LPS and bacteria in the bloodstream. They will be tested in benchtop and animal trials, validating their safety and efficacy in terms of their ability to remove LPS and AMR E. coli from human blood, before full integrating into MediSieve’s extra-corporeal magnetic blood filtration system. At the end of the project, the product will be ready for first in man clinical trials.